This article reviews a concise summary on the updates in COPD including 1) new pathogenic mechanisms and therapeutic targets, 2) management of patients in Group B, C and D according to GOLD 2014 report; 3) prevention and management of exacerbation; 4) monitoring of natural history; and 5) essential but usually forgotten parts of the management.
📌 3 Maddede Bu Makale
🎯
Amaç & Hipotez:Chronic obstructive pulmonary disease (COPD) is a major cause of morbidity and mortality in the world.
📊
Temel Bulgular & Veri:Research conducted over the past decade has contributed much to our current knowledge of the pathogenesis and treatment of COPD.
💡
Sonuç & Katkı:This article reviews a concise summary on the updates in COPD including 1) new pathogenic mechanisms and therapeutic targets, 2) management of patients in Group B, C and D according to GOLD 2014 report; 3) prevention and management of exacerbation; 4) monitoring of natural history; and 5) essential but usually forgotten parts of the management.
🔬Tür:Literatür & Derleme Çalışması
📍Kapsam:2014 Verileri
⚙️Değişkenler:Alan Parametreleri
Özet
Chronic obstructive pulmonary disease (COPD) is a major cause of morbidity and mortality in the world. Research conducted over the past decade has contributed much to our current knowledge of the pathogenesis and treatment of COPD. Additionally, an evolving literature has recently accumulated information about the management of COPD and also about exacerbations. This article reviews a concise summary on the updates in COPD including 1) new pathogenic mechanisms and therapeutic targets, 2) management of patients in Group B, C and D according to GOLD 2014 report; 3) prevention and management of exacerbation; 4) monitoring of natural history; and 5) essential but usually forgotten parts of the management.
🔖
Bu Makaleye Atıf Yap
ATIŞ, S. N., ÇÖPLÜ, L., GÜRGÜN, A., KÖKTÜRK, N., POLATLI, M., ŞEN, E., UMUT, S., UZASLAN, E., YILDIRIM, N., BARNES, P. J. (2015). Updates in chronic obstructive pulmonary disease for the year 2014. Turkish Thoracic Journal, Cilt: 16 - Sayı: 2, 86–96. https://ajindex.com/articles/418159
[CrossRef] 3. Di Stefano A, Caramori G, Gnemmi I, et al. Th17-related cytokine expression is increased in the bronchial mucosa of stable COPD patients. Clin Exp Immunol 2009
[CrossRef] 4. Barnes PJ. Corticosteroid resistance in patients with asthma and chronic obstructive pulmonary disease. J Allergy Clin Immunol 2013
[CrossRef] 5. To Y, Ito K, Kizawa Y, et al. Targeting phosphoinositide-3-ki- nase-d with theophylline reverses corticosteroid insensitivity in COPD. Am J Resp Crit Care Med 2010
[CrossRef] 6. Donnelly LE, Barnes PJ. Defective phagocytosis in airways dis- ease. Chest 2012
[CrossRef] 7. Nakamaru Y, Vuppusetty C, Wada H, et al. A protein deacety - lase SIRT1 is a negative regulator of metalloproteinase-9. FASEB J 2009
[CrossRef] 8. Barnes PJ, Celli BR. Systemic manifestations and comorbidities of COPD. Eur Respir J 2009
[CrossRef] 9. Paschalaki KE, Starke RD, Hu Y, et al. Dysfunction of endothelial progenitor cells from smokers and COPD patients due to increased DNA damage and senescence. Stem Cells 2013
[CrossRef] 10. Barnes PJ. New anti-inflammatory treatments for chronic ob- structive pulmonary disease. Nat Rev Drug Discov 2013
[CrossRef] 11. Global initiative for chronic obstructive airway diseases. Glob- al strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. Updated 2014. http:// www.goldcopd.org. 12. Agusti A, Edwards LD, Celli B, et al. Characteristics, stability and outcomes of the 2011 GOLD COPD groups in the ECLIPSE cohort. Eur Respir J 2013
[CrossRef] 13. Lange P, Marott JL, Vestbo J, et al. Prediction of the clinical course of chronic obstructive pulmonary disease, using the new GOLD classification. Am J Respir Crit Care Med 2012
[CrossRef] 14. Calverley P, Pauwels R, Vestbo J, et al. Combined salmeterol and fluticasone in the treatment of COPD: a randomised controlled trial. Lancet 2003
[CrossRef] 15. Celli BR, Thomas NE, Anderson JA, et al. Effect of pharmacotherapy on rate of decline of lung function in COPD: results from the TORCH study. Am J Respir Crit Care Med 2008
[CrossRef] 16. National Institute for Health and Clinical Excellence (NI